Valion Bio Inc. (VBIO)
VBIO trades on Nasdaq in Health Care, Biotechnology: Electromedical & Electrotherapeutic Apparatus. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2024-12-31, https://www.sec.gov/Archives/edgar/data/1787740/000095017025043234/0000950170-25-043234-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2024-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | VBIO on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Country | United States |
| IPO year | 2021 |
| SEC CIK | 0001787740 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2024
| Line | Value |
|---|---|
| Revenue | $780K |
| Net income | -$5.7M |
| Operating income | -$4.5M |
| Net margin | -725.0% |
| Operating margin | -573.8% |
| Revenue growth | -33.7% |
| Cash | $2.0M |
| Total assets | $2.8M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 1.5× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "The aforementioned factors raise substantial doubt about the Company's ability to continue as a going concern within one year from the issuance date of the consolidated financial statements." | 10-Q 2026-08-14 |
| Cash and burn | $2.1M cash; operating cash flow -$3.6M a quarter. | Report 2026-06-30 |
| Shares outstanding | No cover-page share count in XBRL | Cover page 2026-08-13 |
| Reverse splits, 3 years | 2; latest 1-for-25 on 2026-08-31 | Source 2026-08-31 |
| Shelf and offerings, 12 months | 4 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-10-16 |
| Exchange deficiency notices, 12 months | 1 (8-K item 3.01) | 8-K 2026-03-20 |
| Auditor | Rosenberg Rich Baker Berman, P.A., Somerset, New Jersey, United States | PCAOB Form AP 2026-04-27 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $28K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | Not filed | -$7.1M | -$5.3M | $2.1M | $7.4M | Needs four quarters | 10-Q 2026-08-14 |
| Q1 2026 2026-03-31 | Not filed | -$6.2M | -$5.0M | $7.2M | $6.9M | Needs four quarters | 10-Q 2026-08-14 |
| Q4 2025 2025-12-31 | Not filed | -$2.8M | -$2.3M | $12.6M | $6.5M | Needs four quarters | 10-K 2026-03-30 |
| Q3 2025 2025-09-30 | $146K | -$2.6M | -$2.0M | $3.5M | No debt tags | $482K | 10-Q 2025-11-14 |
| Q2 2025 2025-06-30 | $86K | -$1.9M | -$1.8M | $1.2M | No debt tags | $462K | 10-Q 2025-08-14 |
| Q1 2025 2025-03-31 | $70K | -$1.5M | -$889K | $669K | No debt tags | $516K | 10-Q 2025-05-15 |
| Q4 2024 2024-12-31 | $180K | -$1.5M | -$1.4M | $2.0M | $0 | $780K | 10-K 2025-03-21 |
| Q3 2024 2024-09-30 | $126K | -$1.4M | -$1.4M | $2.2M | No debt tags | $957K | 10-Q 2024-11-14 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2026-10-21 |
| Latest annual report FORM 10-K | 10-K | 2026-03-30 |
| Latest quarterly / interim FORM 10-Q | 10-Q | 2026-08-14 |
| Latest current report FORM 8-K | 8-K | 2026-11-16 |
| Latest proxy DEFINITIVE PROXY STATEMENT | DEF 14A | 2026-10-16 |
Source: SEC EDGAR submissions feed, 407 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +3.7% |
| 1 month | -65.9% |
| 3 months | -87.6% |
| Year to date | -98.5% |
| 1 year | -99.0% |
| From 52-week high | -99.2% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Electromedical & Electrotherapeutic Apparatus
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| NXL | Nexalin Technology Inc. | $1.56 | +2.30% | $1.9M |
| NUWE | Nuwellis Inc. | $4.48 | -8.57% | $2.4M |
| NDRA | ENDRA Life Sciences Inc. | $4.42 | -1.78% | $6.6M |
| IRIX | IRIDEX Corporation | $0.6878 | -0.32% | $12.1M |
| ITOC | iTonic Holdings Ltd | $1.88 | -5.05% | $13.8M |
| QTI | QT Imaging Holdings Inc. | $1.80 | -4.26% | $26.4M |
| ECOR | electroCore Inc. | $4.84 | -7.81% | $44.7M |
| POCI | Precision Optics Corporation Inc. | $4.97 | -4.97% | $54.6M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier